NCT00572975已完成4 期
MALABSORPTION BLOOD TEST: Toward a Novel Approach to Quantify Steatorrhea
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 9
- 试验地点
- 2
- 主要终点
- Aim 1:Comparing Gastric Emptying and Small Bowel Transit Protocol in Healthy Controls
研究概览
简要总结
*The purpose of this study is to develop a more accurate, reliable, specific and more acceptable alternative clinical test to the 72-hour stool and diet collection for quantifying fat malabsorption in people with CF and pancreatic insufficiency.
详细描述
- Nine subjects with CF will be recruited to complete the MBT on two separate occasions, with different doses of pancreatic enzymes
- At each MBT visit, subjects will receive a specific enzyme dose just before they drink the test meal (shake)
- Fat absorption is maximized when the enzymes are taken with the shake.
- If subjects usually receive brands of pancreatic enzymes different from Creon, their dose will be converted to an equivalent dose of Creon 20 for the study.
Prior to each study visit all subjects will be required to:
- Eat their usual diet for 2 days prior to MBT
- Refrain from consuming alcohol or dairy products for 24 hours prior to MBT
- Refrain from non-routine physical exercise for 20 hours prior to MBT
- Adhere to a 12-hour fast prior to MBT (from 8 PM previous night)
- Can drink water from 8:00 PM on the night before the test to 2:00 AM on the day of the test
- At visits 1 and 2, blood samples will be obtained at hourly intervals over a period of eight hours.
- Samples will be analyzed for PA, HA and Triglyceride concentrations.
- Patients will be permitted to ingest non-caloric and non-caffeinated beverages.
- At hour 6, patients will be provided 1000 Kcal, low fat (12 grams of fat) lunch meal.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 8 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects with cystic fibrosis and pancreatic insufficiency (n=9), 8 years of age or older, in usual state of good health will be eligible to participate in this Aim.
- •Subjects will be screened for genotype and a history of pancreatic insufficiency (PI). PI will be confirmed by measurement of fecal elastase 1< 200 mg/g stool.
排除标准
- •Subjects will be ineligible if they have an FEV1 % predicted of < 40%, a history of fibrosing colonopathy or any significant bowel resection (>10 cm) with the exception of a routine, uncomplicated appendectomy.
- •Subjects with diabetes mellitus or disorders associated with altered energy metabolism (i.e. hypothyroidism), or any major illnesses that affect the gastrointestinal tract, will not be eligible for the study.
- •Subjects with significant liver disease, or significant developmental delay will also be excluded.
- •Subjects will be excluded if they have a food allergy related to any components of the experimental shake (i.e., soy or chocolate) or the stool marker, carmine red.
- •Subjects who are pregnant are not eligible. Subjects with a history of intolerance or allergy to Creon 20 will be excluded from the study.
结局指标
主要结局
Aim 1:Comparing Gastric Emptying and Small Bowel Transit Protocol in Healthy Controls
时间窗: 72 hours
次要结局
- Aim 2:The results will establish which pattern of timing of enzyme ingestion results in optimal fat absorption of PA and HA. The results will also elucidate the role of gastric emptying and small bowel transit in subjects in CF.(12-hour fast on 4 separate occasions, each at least 5 days apart)
- Aim 3: The results will establish the reproducibility of MBT as well as estimate the fecal loss of odd chain fatty acids (PA & THA)(12-hour fast on three separate occasions, each at least 5 days apart)
- Aim 4: Dosage Titration Protocol is being tested in order to see changes in absorption with MBT(12-hour fast on two separate occasions)
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
不适用
A Prospective Study of a New Immunochemical Fecal Occult Blood Test in U.S. Veteran Patients Undergoing ColonoscopyColon CancerNCT00533975University of California, San Diego500
已完成
1 期
Evaluation of Whole Blood With CPD Anticoagulant and AS-7/SOLX Additive SolutionBlood DonorsNCT02145507Haemonetics Corporation170
终止
不适用
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated MelanomaMelanomaNCT03727087Exact Sciences Corporation348
终止
不适用
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Hematologic MalignanciesHematologic MalignancyNCT03727009Exact Sciences Corporation409
已完成
不适用
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid TumorsBreast CancerColorectal CancerLung CancerUterine CancerKidney CancerRenal Pelvis CancerProstate CancerOvarian CancerPancreatic CancerBladder CancerEsophageal CancerLiver CancerStomach CancerNCT03662204Exact Sciences Corporation5,133